Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Cheung
    Cheung
  8. Voss
    Voss
  9. O'Reilly
    O'Reilly
  10. Robson
    Robson

Groups

  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)
  7. Epidemiology and Biostatistics (151)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (121)
  10. Surgery (118)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Roberta Zappasodi (24)

More People

Years
  1. 2025 (28)
  2. 2024 (63)
  3. 2023 (45)
  4. 2022 (123)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (404)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (46)
  5. Journal of Hematology & Oncology (42)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NKTR-255+cetuximab in patients with solid tumors: Interim safety and efficacy results from the phase 1b dose-escalation study
    Meeting Abstract

    Altan, M.; Patnaik, A.; Barve, M.; Dunn, L.; Cobb, P.; Rosenberg, A.; Sharma, S.; Sukari, A.; Patel, M.; Wang, X.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; George, M.; Venkatesh, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Combining a novel dual RAF/MEK inhibitor with immunomodulation to promote an anti-tumor response
    Meeting Abstract

    Dong, L.; Choi, H.; Budhu, S.; Schulze, I.; Mehanna, N.; Rosen, N.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy
    Meeting Abstract

    Verma, S.; Maniyar, R.; Ko, M.; Budhu, S.; Serganova, I.; Zappasodi, R.; Blasberg, R.; Merghoub, T.; Wolchok, J.; Mangarin, L.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Single-cell RNA-seq reveals the critical roles of the sting- and MDA5-mediated cytosolic nucleic acid-sensing pathways as well as IFNAR/STAT2 signaling in recombinant MVA-induced antitumor immunity
    Meeting Abstract

    Liu, S.; Mazo, G.; Zhang, T.; Yang, N.; Wang, Y.; Tan, A.; Wang, J.; Choi, J.; Xiang, J. Z.; Merghoub, T.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
    Meeting Abstract

    Sacco, J.; Carvajal, R.; Butler, M.; Shoushtari, A.; Hassel, J.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
    Meeting Abstract

    Hamid, O.; Hassel, J.; Shoushtari, A.; Meier, F.; Bauer, T.; Salama, A.; Kirkwood, J.; Ascierto, P.; Lorigan, P.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
    Meeting Abstract

    Naing, A.; Callahan, M.; Costello, B.; Curti, B.; Hall, E.; Hansen, A.; Long, G.; Joshua, A.; Shankles, B.; Ulge, U.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of stroma poor cancers
    Meeting Abstract

    Budhu, S.; Gupta, A.; Fitzgerald, K.; Giese, R.; Michel, A.; Holland, A.; Campesato, L. F.; Van Snick, J.; Uyttenhove, C.; Ritter, G.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M.; Cho, B.; Juergens, R.; Cheng, Y.; de Castro, G.; Erman, M.; Bauman, J.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save